Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
- Teijin Grants Global Rights for Kidney Disease Med to Novartis
March 7, 2023
- FDA Accepts Eisai’s Lecanemab Application for Early July Target
March 6, 2023
- Generic Makers See Milder Cuts in FY2023 Revision, Nipro to Get 1%-Plus Net Hike: Jiho Poll
March 6, 2023
- 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
- Sumitomo Pharma Drops Cancer Drug Candidate Dubermatinib
March 6, 2023
- Alfresa Pharma Gets Japan Rights to Keio Biotech’s ALS Drug
March 3, 2023
- Biogen Japan, Eisai to End MS Copromotion Pact in Japan
March 3, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Eylea 8 mg Filed in Japan to Extend Dosing Intervals: Bayer
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- AstraZeneca Files Anti-RSV Antibody Nirsevimab in Japan
March 1, 2023
- Nippon Chemiphar Out-Licenses XOR Inhibitor to Chinese Pharma
March 1, 2023
- UCB Japan Files Rozanolixizumab for Generalized Myasthenia Gravis
March 1, 2023
- Ono Seeks Japan Nod for Malignant Mesothelioma for Opdivo
March 1, 2023
- Actemra Filed in Japan for CRS Induced by Cancer Treatment: Chugai
March 1, 2023
- Lecanemab Earns Priority Review Status in China: Eisai
March 1, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…